Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nucana Plc ADR (NQ: NCNA )

1.245 -0.025 (-1.97%)
Streaming Delayed Price Updated: 11:32 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nucana Plc ADR

< Previous 1 2 Next >
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
From NuCana plc
Via GlobeNewswire
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
From NuCana plc
Via GlobeNewswire
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety Profile 
From NuCana plc
Via GlobeNewswire
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
From NuCana plc
Via GlobeNewswire
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
NuCana to Present at the Jefferies Global Healthcare Conference
From NuCana plc
Via GlobeNewswire
NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit
From NuCana plc
Via GlobeNewswire
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
From NuCana plc
Via GlobeNewswire
NuCana Announces Completion of ADS Ratio Change
From NuCana plc
Via GlobeNewswire
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study
From NuCana plc
Via GlobeNewswire
NuCana Announces Plan to Implement ADS Ratio Change
From NuCana plc
Via GlobeNewswire
NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
NuCana to Present at TD Cowen’s 44th Annual Health Care Conference
From NuCana plc
Via GlobeNewswire
NuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From NuCana plc
Via GlobeNewswire
NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
NuCana Announces Listing Transfer to Nasdaq Capital Market
From NuCana plc
Via GlobeNewswire
NuCana to Present at the Jefferies London Healthcare Conference
From NuCana plc
Via GlobeNewswire
NuCana to Participate in the Truist Securities 2023 BioPharma Symposium
From NuCana plc
Via GlobeNewswire
NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
From NuCana plc
Via GlobeNewswire
NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
From NuCana plc
Via GlobeNewswire
NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
From NuCana plc
Via GlobeNewswire
NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
NuCana to Present at the Jefferies Healthcare Conference
From NuCana plc
Via GlobeNewswire
NuCana Reports First Quarter 2023 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
NuCana Announces Receipt of Nasdaq Notice
From NuCana plc
Via GlobeNewswire
NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action
From NuCana plc
Via GlobeNewswire
NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana’s ‘190 Patent is Not Valid
Ruling Has No Impact on NuCana’s Anti-Cancer ProTide Patents 
From NuCana plc
Via GlobeNewswire
NuCana to Participate in Two Upcoming Investor Conferences
From NuCana plc
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.